PSGRX Mutual Fund

PSGRX Mutual Fund

NAV$76.72
See how much of PSGRX you already own
Just $25 once·$99/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of Sep 30, 2026

Net Assets
$13M
Expense Ratio
1.42%
Dividend Yield (Current)
-
Holdings
102
Inception Date
Dec 1, 2003
Fund Family
Putnam Investments
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD+6.37%
1 Year+2.44%
3 Year+18.99%
5 Year+3.79%
10 Year+13.95%

Asset Allocation

Stocks: 96.09%
Bonds: 1.70%
Other: 2.20%
See how much of PSGRX you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report comes with FundXLS. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
DOCNDigitalOcean Holdings Inc2.54%
HALOHalozyme Therapeutics Inc2.44%
HURNHuron Consulting Group Inc2.25%
ROLLRbc Bearings Inc2.19%
BTSGBrightSpring Health Services Inc2.02%
Top 10 Concentration: 20.56%Report Date: Sep 30, 2026
Download all 102 holdings for PSGRX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Frequency
Annually
Latest Distribution
$10.34
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

PSGRX Mutual Fund Overview

PSGRX Mutual Fund (Putnam Small Cap Growth Fund Class R) is managed by Putnam Investments with $13.2M in net assets. PSGRX expense ratio is 1.42%, holding 102 positions across sectors including Health Care, Information Technology, Industrials. Inception date: 2003-12-01.

PSGRX performance shows a YTD return of 6.37%. The 1-year return is 2.44% and the 5-year return is 3.79%.

PSGRX top holdings include DigitalOcean Holdings Inc (2.5%), Halozyme Therapeutics Inc (2.4%), Huron Consulting Group Inc (2.3%), Rbc Bearings Inc (2.2%), BrightSpring Health Services Inc (2.0%). Go to all PSGRX holdings, PSGRX sectors, or PSGRX dividends.

PSGRX can be compared against other funds. Use PSGRX overlap to find shared positions, or PSGRX vs another fund for a side-by-side view. PSGRX alternatives are available via the screener, along with tax-loss harvesting opportunities.